A Phase IIb Study of ABT 494, a Selective JAK 1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti Tumor Necrosis Factor Therapy
To compare the efficacy and safety of ABT 494, a novel selective JAK 1 inhibitor, with placebo in patients with moderate to severe rheumatoid arthritis (RA) and an inadequate response or intolerance to at least 1 anti tumor necrosis factor (anti TNF) agent.
Arthritis rheumatology